Marco Metra, John R Teerlink, Gad Cotter, Beth A Davison, G Michael Felker, Gerasimos Filippatos, Barry H Greenberg, Peter S Pang, Piotr Ponikowski, Adriaan A Voors, Kirkwood F Adams, Stefan D Anker, Alexandra Arias-Mendoza, Patricio Avendaño, Fernando Bacal, Michael Böhm, Guillermo Bortman, John G F Cleland, Alain Cohen-Solal, Maria G Crespo-Leiro, Maria Dorobantu, Luis E Echeverría, Roberto Ferrari, Sorel Goland, Eva Goncalvesová, Assen Goudev, Lars Køber, Juan Lema-Osores, Phillip D Levy, Kenneth McDonald, Pravin Manga, Béla Merkely, Christian Mueller, Burkert Pieske, Jose Silva-Cardoso, Jindřich Špinar, Iain Squire, Janina Stępińska, Walter Van Mieghem, Dirk von Lewinski, Gerhard Wikström, Mehmet B Yilmaz, Nicole Hagner, Thomas Holbro, Tsushung A Hua, Shalini V Sabarwal, Thomas Severin, Peter Szecsödy, Claudio Gimpelewicz
BACKGROUND: Serelaxin is a recombinant form of human relaxin-2, a vasodilator hormone that contributes to cardiovascular and renal adaptations during pregnancy. Previous studies have suggested that treatment with serelaxin may result in relief of symptoms and in better outcomes in patients with acute heart failure. METHODS: In this multicenter, double-blind, placebo-controlled, event-driven trial, we enrolled patients who were hospitalized for acute heart failure and had dyspnea, vascular congestion on chest radiography, increased plasma concentrations of natriuretic peptides, mild-to-moderate renal insufficiency, and a systolic blood pressure of at least 125 mm Hg, and we randomly assigned them within 16 hours after presentation to receive either a 48-hour intravenous infusion of serelaxin (30 μg per kilogram of body weight per day) or placebo, in addition to standard care...
August 22, 2019: New England Journal of Medicine